Joanne Holland
Hoofd Techniek/Wetenschap/O&O bij CONDUIT PHARMACEUTICALS INC.
Profiel
Joanne Holland is the founder of Nuformix Plc, which was founded in 2008.
She held the title of Executive Director in 2021.
Currently, Dr. Holland is the Chief Scientific Officer at Conduit Pharmaceuticals, Inc. since 2024.
Previously, she worked at Nuformix Technologies Ltd.
as the Director, Chief Scientific & Technology Officer from 2008 to 2021.
Dr. Holland obtained a doctorate degree from the University of Leeds.
Actieve functies van Joanne Holland
| Bedrijven | Functie | Begin |
|---|---|---|
| CONDUIT PHARMACEUTICALS INC. | Hoofd Techniek/Wetenschap/O&O | 19-03-2024 |
Eerdere bekende functies van Joanne Holland
| Bedrijven | Functie | Einde |
|---|---|---|
Nuformix Technologies Ltd.
 Nuformix Technologies Ltd. Pharmaceuticals: MajorHealth Technology Nuformix Technologies Ltd. engages in investment in pharmaceutical products. Its activities include development and discovery of patented novel cocrystal forms of approved small molecules, creating an IP portfolio containing 14 granted patents covering cocrystal forms of five small molecule drugs. It offers the NXP001 and NXP002. The company was founded by Dr. David Joszef Tapolzcay and Dr. Daniel Gooding on October 23, 2007 and is headquartered in Cambridge, the United Kingdom. | Hoofd Techniek/Wetenschap/O&O | 31-05-2021 |
| NUFORMIX PLC | Oprichter | 31-05-2021 |
Opleiding van Joanne Holland
| University of Leeds | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| NUFORMIX PLC | Health Technology |
| CONDUIT PHARMACEUTICALS INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Nuformix Technologies Ltd.
Nuformix Technologies Ltd. Pharmaceuticals: MajorHealth Technology Nuformix Technologies Ltd. engages in investment in pharmaceutical products. Its activities include development and discovery of patented novel cocrystal forms of approved small molecules, creating an IP portfolio containing 14 granted patents covering cocrystal forms of five small molecule drugs. It offers the NXP001 and NXP002. The company was founded by Dr. David Joszef Tapolzcay and Dr. Daniel Gooding on October 23, 2007 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
